FDA Investigator Edward Oshaughnessy
Edward Oshaughnessy has inspections in 17 countries as of 13 Oct 2023. Edward Oshaughnessy has collaborated with a combined 3194 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
339
Last Inspection Date:
13 Oct 2023
Investigator Role:
FDA Investigator
Redica ID:
Country:
United States of America,
India,
Canada,
Bulgaria,
Jamaica,
China,
Malaysia,
Belgium,
United Kingdom of Great Britain and Northern Ireland,
Trinidad and Tobago,
Turkey,
Viet Nam,
Peru,
Japan,
Germany,
Mexico
Co-Investigator(s):
A Williams,
Albert M Brindle,
Althea A Williams,
Amy L Singer,
Amy M Codella,
Amy M Cramer,
Ana S Cabrera,
Anastasia I Offordile,
Andrew F Cohen,
Annemarie Bodnar,
Annemarie Kleiza,
Anthony M Criscuolo, Jr,
Antoinette L Ravelli,
Arduino Frankovic,
Arlyss M Jones,
Atul J Agrawal,
Barbara J Maulfair,
Barbara Jwilimczyk Macri,
Brian D Young,
Brian R Yaun,
Brian Ravitch,
Byungja E Marciante,
Carol A Perry,
Carol A Robles,
Cary Greene,
Charisse K Green,
Charles J Chacko,
Charles M Edwards,
Charlotte P Chang,
Cherie T Parker,
Christina N Maurino,
Craig W Swanson,
David A Schwartz,
David G Whitman,
David H Smith,
David J Leray,
Dawn L Wydner,
Dena M Elimam,
Denise M Visco, Investigator,
Dennis L Doupnik,
Derek S Dealy,
Dessa A Antoine,
Devon Jenkins,
Dhaval H Patel,
Diana K Krepel,
Doreen P Gubbay,
Dorothy J Denes,
Edith M Gonzalez,
Edward O'shaughnessy,
Edward O'shaugnessy,
Elizabeth D Connell,
Elizabeth P Mayer,
Emest F Bizjak,
Emmanuel J Ramos,
Eric Rothschild,
Esteban Beltran,
Felix Maldonado,
Frank J Marciniak,
Frederick Razzaghi,
Gale L Glinecki,
Gianine E Delade,
Gianine E Tompkins,
Gobiga Vanniyasingam,
Grant L Davis,
Harperd,
Herrmann,
Hitesh R Patel,
Huy T Pham,
Jacqueline A O'shaughnessy, PhD,
James R Birkenstamm,
Janaye A Young,
Jane Chen,
Jason M Sluzynski,
Jason P Aun,
Jean M Kelahan,
Jennifer A Bazergui,
Jennifer A Robinson,
Jennifer L Custodio,
Jennifer Macmillan,
Jennifer R Mathern,
Jessica M Monteiro,
Jo Annc Declement,
Jonathan T Little,
Jonee J Mearns,
Jose M Cayuela,
Jose R Hernandez,
Joseph Duca,
Juan D Lopez,
Judith A Jones,
Judith A Paterson,
Justine Tomasso,
K Gonzlez,
Karen F Tomaziefski,
Karen M Labounty,
Karla J Gibler,
Kathleen J Close,
Keith A Schwartz,
Kelli A Giannattasio,
Kelli F Dobilas,
Kelly Doremus,
Kelly I Anderson,
Kenneth Nieves,
Kerry A Kurdilla,
King,
Kinh Q Mac,
Kris K Moore,
Kristen E Rescigno,
Kristy A Zielny,
Kyle D Covill,
Laishan L Lam,
Larry K Austin,
Lata C Mathew, PhD,
Lauren E Sexton,
Lauren L Vajo,
Lawrence R Johnson,
Li Li,
Lisa B Hall,
Lisa Mathew,
Lorna F Jones,
LT Luis O Rodriguez,
LTJG Matthew R Palo,
Marcellinus D Dordunoo,
Marcelo O Mangalindan, Jr,
Maria Estrella,
Marjorie D Schultz,
Matthew A Johnson,
Megan E Kerry,
Megan E Kulas,
Melissa A Freeman,
Melissa A Zuppe,
Melissa B Libby,
Melissa T Roy,
Melka F Argaw,
Meredith L Sheridan,
Meyer,
Michael E Campbell,
Michael Rosner,
Michael Serrano,
Michelle M Parisi,
Mielziner,
Mohammed H Adam,
Monica L Guitierrez,
Monica L Gutierrez,
Msdap Gonzlezk,
Nancy F Scheraga,
Neal D Singletary, PhD,
Nerizza B Guerin,
Nianna C Burns,
Nicholas A Violand,
Pedro A Cruz,
Peter M Trunk,
Phal K Chhun,
Ramanda C Gregory,
Raymond L Cheung,
Regina T Brown,
Remache,
Rene M Amaguana,
Richard D Manney,
Robert G Ruff,
Robert W Calais,
Rodrigo Vilchez,
Rupa Pradhan,
Saleem A Akhtar,
Sandra Kershaw,
Sands,
Sarah Forney,
Schultz,
Sean D Duke,
Sean G Casey,
Seng Ching Hwang,
Sherri J Liu,
Sinai Davis,
Sonia D Hudson,
State Agency,
Stephanie T Durso,
Steven S Wahl,
Susan M Halsted,
Tegan M Vanartsdalen,
Teigan M Mule,
Thomas J Hudson,
Tracy M Portelli,
Tressa T Lewis,
Valerie C Reed,
Wayne J Meyer,
William J Muszynski,
William W Dotts,
Young M Yoon,
Zakaria I Ganiyu
Edward Oshaughnessy's Documents
Publish Date | Document Type | Title |
---|---|---|
March, 2002 | FDA 483 Response | Ethicon, Inc. - Form 483R, 2002-03-25 |
April, 2003 | EIR | Zebu Enterprises, LLC - EIR, 2003-04-30 |
September, 2010 | FDA 483 | Vita Pure, Inc. - Form 483, 2010-09-23 |
March, 2002 | EIR | Ethicon, Inc. - EIR, 2002-03-25 |
September, 2011 | FDA 483 | Beaver-Visitec International, Inc. - Form 483, 2011-09-16 |
May, 2014 | FDA 483 | Flawless Beauty LLC - Form 483, 2014-05-16 |
December, 2003 | EIR | Arctic Products Company Inc. - EIR, 2003-12-11 |
April, 2003 | FDA 483 | Zebu Enterprises, LLC - Form 483, 2003-04-30 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more